Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Declines By 62.9%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 91,000 shares, a decline of 62.9% from the August 31st total of 245,200 shares. Based on an average trading volume of 599,300 shares, the days-to-cover ratio is presently 0.2 days. Approximately 6.8% of the company’s stock are short sold.

Theriva Biologics Price Performance

Shares of Theriva Biologics stock traded down $0.32 during trading on Thursday, hitting $2.05. 1,787,290 shares of the stock were exchanged, compared to its average volume of 230,034. The firm has a market capitalization of $82,000.00, a PE ratio of -1.78 and a beta of 1.38. Theriva Biologics has a 1-year low of $1.78 and a 1-year high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.22) earnings per share for the quarter.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.